Online citations, reference lists, and bibliographies.

Cognitive Dysfunction And Dementia In Parkinson’s Disease

J. Bosboom, D. Stoffers, E. C. Wolters
Published 2004 · Psychology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Summary.Parkinson’s disease (PD) is a slowly progressive neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and the ventral tegmental area, in combination with a varying loss of central noradrenergic (locus coeruleus), cholinergic (nucleus basalis of Meynert) and serotonergic (dorsal raphe nuclei) integrity, leading to a multitude of motor and non-motor behavioral disturbances.Apart from the clinical motor hallmarks, in the early stages of disease, subtle cognitive dysfunction might be seen comprising mainly executive dysfunction, with secondary visuospatial and mnemonic disturbances. In about 20–40% of patients, these problems may eventually proceed to dementia, which constitutes an important risk factor for caregiver distress, decreased quality of life and nursing home placement. Dementia in PD is typically characterized by a progressive dysexecutive syndrome with attentional deficits and fluctuating cognition, often accompanied by psychotic symptoms. It is thought to be the result of a combination of both subcortical and cortical changes. PD-related dopaminergic deficiency in the nucleus caudatus and mesocortical areas (due to degeneration of projections from the substantia nigra and ventral tegmental area) and cholinergic deficiency in the cortex (due to degeneration of ascending projections from the nucleus basalis of Meynert), combined with additional Alzheimer-pathology and cortical Lewy bodies, may greatly contribute to dementia.Current treatment of dementia in PD is based on compensation of the profound cholinergic deficiency. Recent studies with the cholinesterase inhibitors galantamine, donepezil and rivastigmine show promising results in improving cognition and ameliorating psychotic symptoms, which must further be confirmed in randomized controlled trials.
This paper references
10.1007/s007020100008
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia
E. A. Werber (2001)
Studies on mesocortical dopamine systems.
A. M. Thierry (1978)
10.1037/0894-4105.7.1.89
Contributions of Frontal System Dysfunction to Memory and Perceptual Abilities in Parkinson's Disease
Mark W. Bondi (1993)
10.1016/0278-2626(90)90051-O
Memory and learning in early Parkinson's disease: Evidence for a “frontal lobe syndrome”
A. Taylor (1990)
10.1016/0028-3932(93)90135-M
Visuospatial memory deficits at different stages of Parkinson's disease
A. Owen (1993)
10.1002/mds.10455
Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study.
David J. Burn (2003)
10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
J. Kulisevsky (2000)
10.1016/S0028-3932(97)00102-4
Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on ‘strategic’ processes?
Bernard Pillon (1998)
10.1001/archneur.55.7.969
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.
Irene Litvan (1998)
10.1212/WNL.37.7.1130
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease
R. Mayeux (1987)
Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
K. Lange (1995)
10.1002/cne.902870308
Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
V. Chan-Palay (1989)
10.1185/030079902125000813
Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series
R. Bullock (2002)
10.1002/mds.10567
Psychosis in Parkinson's disease.
Werner Poewe (2003)
10.1001/archneur.59.1.102
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.
H. Apaydin (2002)
10.1212/WNL.43.9.1690
Antecedent clinical features associated with dementia in Parkinson's disease
Yaakov Stern (1993)
10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z
Mental symptoms in Parkinson's disease are important contributors to caregiver distress.
D. Aarsland (1999)
10.1002/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0
Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.
Clive G Ballard (2000)
10.1001/archneur.1984.04050170031011
Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors.
F. Boller (1984)
10.2165/00002512-200016050-00006
Role of Dopamine in Learning and Memory
Jaime Kulisevsky (2000)
10.1212/WNL.54.12.2269
A 5-month, randomized, placebo-controlled trial of galantamine in AD
P. Tariot (2000)
10.1006/brcg.1999.1083
Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome
M. Bédard (1999)
10.1017/S1355617703910022
Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease.
S. Woods (2003)
10.1111/j.1532-5415.2000.tb06891.x
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
D. Aarsland (2000)
10.1016/S0010-9452(13)80179-7
Encoding Deficits in Untreated Parkinson's Disease
James A. Cooper (1993)
10.1002/ana.410130304
Basal forebrain neurons in the dementia of Parkinson disease.
P. Whitehouse (1983)
10.1002/mds.1204
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
P J Reading (2001)
Psychiatric complications in the treatment of Parkinson's disease.
Erik Ch. Wolters (2001)
10.1001/archneur.55.7.994
Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease.
D. Connor (1998)
10.1097/00002826-200203000-00009
Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease
Joseph A. Bergman (2002)
10.1212/WNL.55.4.539
Motor impairment in PD
Gilberto Levy (2000)
10.1001/archneur.1993.00540040036010
Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.
B. Pillon (1993)
10.1093/brain/109.5.845
Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow.
A. Taylor (1986)
10.1136/jnnp.51.12.1498
Dementia and cognitive impairment in Parkinson's disease.
Floriano Girotti (1988)
10.1034/j.1600-0404.2003.00211.x
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Nir Giladi (2003)
10.1016/0165-0173(87)90011-7
Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity
R. Oades (1987)
10.1007/s004019900168
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease
P. Mattila (2000)
10.1007/BF01249089
Dementia in idiopathic Parkinson's disease
Teresita S. Elizan (1986)
10.1001/archneur.1989.00520480029015
Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases.
S. Huber (1989)
Ventral segmental (A10) system: neurobiology
RD Oades (1987)
Psychosis in Parkinson's disease Visuoperception and visuospatial and visuorotational performance in Parkinson's disease
W Poewe (1987)
10.1016/0197-4580(92)90113-C
Convergent cholinergic activities in aging and Alzheimer's disease
E. Perry (1992)
10.1016/0028-3932(94)90135-X
Memory and learning strategies in patients with Parkinson's disease
Elly L. Buytenhuijs (1994)
10.1007/s004010100372
Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment
P. Mattila (2001)
10.1001/archneur.60.3.387
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.
D. Aarsland (2003)
10.1007/978-3-642-70644-8_5
Cognitive Deficits in Parkinson’s Disease
A. Lees (1985)
Mental dysfunctions in Parkinson ’ s disease
EC Wolters (1998)
10.1212/WNL.37.1.42
Parkinson's disease and dementia
R. Cash (1987)
10.1002/mds.10280
Memory and executive function impairment predict dementia in Parkinson's disease.
G. Levy (2002)
10.1002/ana.410400309
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.
D. Kuhl (1996)
10.1136/jnnp.45.12.1161
Confusion, dementia and anticholinergics in Parkinson's disease.
Y de Smet (1982)
10.1212/WNL.45.9.1691
Neuropsychological characteristics of preclinical dementia in Parkinson's disease
D. M. Jacobs (1995)
Dementia in Parkinon’s disease: subclinical Alzheimer’s disease? In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson’s disease
Scheltens Ph (1999)
Dementia in Parkinon's disease: subclinical Alzheimer's disease? In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II
Scheltens Ph (1999)
10.1136/jnnp.61.3.324-a
Cholinesterase inhibition in Parkinson's disease.
Michael Hutchinson (1996)
10.1017/S104161020100758X
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.
J B Grace (2001)
10.1093/brain/121.5.815
Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease.
R. Rogers (1998)
10.1136/jnnp.67.4.558
The cholinergic hypothesis of Alzheimer’s disease: a review of progress
T. Babić (1999)
10.1007/s004010100390
Cortical Lewy body pathology in the diagnosis of dementia
A. Harding (2001)
10.1212/WNL.25.8.701
Parkinsonism: Effects of levodopa treatment on concept formation
Florry Proctor Bowen (1975)
10.1126/science.283.5408.1657
Storage and executive processes in the frontal lobes.
E. Smith (1999)
10.1097/00005072-199111000-00006
The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease
W. Paulus (1991)
10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Ian G. McKeith (2000)
Dementia in Parkinson’s disease: incidence and associated factors at 14-years of follow-up
NL Read (2001)
10.1136/jnnp.65.5.804
Neuropsychological prediction of dementia in Parkinson’s disease
T. Hughes (1998)
10.1093/brain/awf036
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions.
J. Rowe (2002)
10.1136/jnnp.52.2.201
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
B. Pillon (1989)
Neuropathological correlates of mental dysfunction in Parkinson’s disease: an update
KA Jellinger (1999)
Dementia in Parkinon ’ s disease : subclinical Alzheimer ’ s disease ?
Scheltens Ph (1999)
Parkinson’s disease and dementia: norepinephrine and dopamine in locus
R Cash (1987)
10.1016/S0733-8619(05)70230-9
Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia.
I. McKeith (2000)
10.1111/j.1749-6632.1991.tb00217.x
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.
E. Perry (1991)
10.1212/WNL.56.6.730
Risk of dementia in Parkinson’s disease
D. Aarsland (2001)
10.1159/000116381
Frontal lobe dysfunction in Parkinson's disease: prognostic value for dementia?
M. Piccirilli (1989)
10.1016/S0022-3999(98)00034-8
Frontal-subcortical circuits and human behavior.
J. Cummings (1993)
Cognitive deficits and dementia in Parkinson's disease Aging and dementia
B Pillon (2001)
10.1111/j.1460-9568.2004.03108.x
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans.
S. Lewis (2004)
10.1136/jnnp.52.11.1228
Visuospatial working memory in Parkinson's disease.
V. A. Bradley (1989)
10.1017/s1355617798466074
Cognitive speed in nondemented Parkinson's disease.
M. C. Smith (1998)
10.1007/s007020200027
Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
K. Jellinger (2002)
10.1093/brain/117.3.517
Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease.
J. Cooper (1994)
10.1212/WNL.54.2.407
Cholinergic dysfunction in diseases with Lewy bodies
P. Tiraboschi (2000)
10.1002/gps.949
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
D. Aarsland (2003)
10.1001/archneur.1996.00550060082020
Frequency of dementia in Parkinson disease.
Dag Aarsland (1996)
10.1007/BF02245167
l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction
K. Lange (2005)
Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease
SL Rogers (1998)
Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson’s disease patients with and without dementia
K SantaCruz (1999)
10.1146/annurev.ne.09.030186.002041
Parallel organization of functionally segregated circuits linking basal ganglia and cortex.
G. E. Alexander (1986)
10.1212/01.WNL.0000036908.39696.FD
Fluctuations in attention
C. Ballard (2002)
10.1097/00002093-199100530-00015
An estimate of the incidence of dementia in idiopathic Parkinson??s disease
R. Mayeux (1991)
10.1002/mds.10274
Parkinson's disease and dementia with Lewy bodies: one disease or two?
I. Richard (2002)
10.1136/jnnp.72.6.708
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
D. Aarsland (2002)
10.1517/eods.3.3.209.31071
Psychotic symptoms in Parkinson's disease: pathophysiology and management.
Johannes L. Bosboom (2004)
10.1136/jnnp.74.9.1215
Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease
D. Aarsland (2003)
10.1093/brain/111.2.299
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.
A. M. Gotham (1988)
10.1002/ana.410260107
Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra.
J. Rinne (1989)
10.1007/BF00718018
Visuoperception and visuospatial and visuorotational performance in Parkinson's disease
Gerhard Ransmayr (1987)
10.1034/j.1600-0404.2000.00310.x
Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
M. Samochocki (2000)
10.1016/S0028-3932(96)00101-7
Spatial and non-spatial working memory at different stages of Parkinson's disease
A. Owen (1997)
10.1093/brain/123.4.733
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
G. Fénelon (2000)
10.1016/0028-3932(72)90027-9
Parkinsonism: alterations in spatial orientation as determined by a route-walking test.
F. P. Bowen (1972)
10.1080/01688639208402864
Set-shifting and spatial orientation in patients with Parkinson's disease.
Sarah A. Raskin (1992)
10.1093/brain/121.5.949
Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions.
A. Owen (1998)
10.1007/s100720200022
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
G. Fabbrini (2002)
10.3233/JAD-2006-9S347
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Ian G. McKeith (1996)
10.1097/00002093-199307020-00002
Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease
E. Perry (1993)
10.1007/s004010050843
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease
P. Mattila (1998)
10.1093/brain/109.5.987
Visuospatial function in Parkinson's disease.
R. Brown (1986)
10.1001/archneur.1995.00540310069018
The frequency and associated risk factors for dementia in patients with Parkinson's disease.
K. Marder (1995)
10.1136/jnnp.48.5.413
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.
E. Perry (1985)
10.1016/S0140-6736(76)91936-X
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
P. Davies (1976)
Deficits on visuospatial tests involving forward planning in high-functioning Parkinsonians
JA Ogden (1990)
Neuropathological correlates of mental dysfunction in Parkinson's disease: an update. In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II
Ka Jellinger (1999)
10.1212/WNL.54.8.1596
A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease
T. Hughes (2000)
10.1016/S0010-9452(80)80022-0
High Speed Memory Scanning in Parkinsonism
R. Wilson (1980)
10.1212/WNL.50.5.1214
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Jeffrey L. Cummings (1998)
10.1002/mds.10566
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
D. Burn (2003)
10.1001/archneur.1992.00530290076015
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender.
Richard P. Mayeux (1992)
Cognitive deficits and structural brain changes associated with dementia and visual hallucinations in Parkinson's disease
Blanca Ruiz (2006)
10.1185/0300799039117029
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions
Carlo Gabelli (2003)
10.1093/brain/115.6.1701
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
J. Cooper (1992)
10.1016/0006-8993(83)90993-9
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
B. Scatton (1983)
10.1001/archneur.1988.00520270034017
An estimate of the prevalence of dementia in idiopathic Parkinson's disease.
R. Mayeux (1988)
10.1212/WNL.50.1.136
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
S. L. Rogers (1998)
10.1016/S0140-6736(00)03399-7
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
I. Mckeith (2000)
10.1002/cne.902140206
Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey.
M. Mesulam (1983)
10.1016/0303-8467(94)00060-J
‘Lewy body disease’: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia
Rob Ai De Vos (1995)
10.1212/WNL.37.3.485
Spatial disorientation as an early symptom of Parkinson's disease
A. Hovestadt (1987)
10.1212/WNL.54.10.1916
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
H. Hurtig (2000)
Cholinergic dysfunction in diseases
P Tiraboschi (2000)
10.1016/0306-4522(83)90108-2
Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6)
M. Mesulam (1983)



This paper is referenced by
10.1007/978-3-642-28711-4
Brain Imaging in Behavioral Neuroscience
Cameron S. Carter (2012)
Intra-individual reaction time variability in sustained attention
Rachel Ann Moss (2018)
10.1016/S0079-6123(10)84016-6
Deep brain stimulation state of the art and novel stimulation targets.
Francisco A. Ponce (2010)
10.1024/1016-264X/A000115
Leichte kognitive Störungen und Demenz bei Patienten mit Morbus Parkinson
Elke Kalbe (2014)
10.1109/CISP-BMEI.2016.7853008
Computer aided analysis of cognitive disorder in patients with Parkinsonism using machine learning method with multilevel ROI-based features
Bo Peng (2016)
10.1155/2012/910757
Cognitive Profiles in Parkinson's Disease and Their Relation to Dementia: A Data-Driven Approach
Inga Liepelt-Scarfone (2012)
BINDING TO CORTICAL MUSCARINIC RECEPTORS IN UNILATERALLY 6-HYDROXYDOPAMINE LESIONED RATS
Remco J. J. Knol (2008)
10.1016/j.jpsychores.2019.05.001
The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses.
Ires Ghielen (2019)
10.3109/07420528.2012.762011
Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of parkinson’s disease
Karim Fifel (2013)
10.1016/j.bandl.2011.05.006
The organization of narrative discourse in Lewy body spectrum disorder
Sharon Ash (2011)
10.1007/s10571-006-9118-9
Heterogeneous Distribution of Kir3 Potassium Channel Proteins Within Dopaminergic Neurons in the Mesencephalon of the Rat Brain
D. Eulitz (2006)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.
M Horstink (2006)
10.5772/21140
Pathophysiology of Non-Dopaminergic Monoamine Systems in Parkinson's Disease: Implications for Mood Dysfunction
Nirmal Bhide (2011)
10.1177/155005941004100303
Functional Imaging of Cognitive Impairment in Parkinson's Disease
Toni Fitzpatrick (2010)
10.1007/s12640-011-9281-8
Intranasal Administration of Neurotoxicants in Animals: Support for the Olfactory Vector Hypothesis of Parkinson’s Disease
R. Prediger (2011)
10.1007/s00415-020-09783-7
Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease
Rocío Del Pino (2020)
10.3389/fnbeh.2014.00405
Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson’s disease
Pietro Cipresso (2014)
10.4018/IJVAR.2018010103
Exploring Virtual Reality for the Assessment and Rehabilitation of Executive Functions
Elisa Pedroli (2018)
Dementia and mild cognitive impairment in patients with Parkinson's disease.
Hélio Afonso Ghizoni Teive (2009)
10.1080/13554790802637743
Conceptual Hypometria? An evaluation of conceptual mapping of space in Parkinson's disease
F. M. Skidmore (2009)
10.3727/096368912X640457
Long-Lasting Paracrine Effects of Human Cord Blood Cells on Damaged Neocortex in an Animal Model of Cerebral Palsy
Sang-Hun Bae (2012)
The endogenous repair capacity of the parkinsonian brain
Simone A. van den Berge (2011)
10.1016/j.neuropsychologia.2011.01.024
A process-model based approach to prospective memory impairment in Parkinson's disease
Matthias Kliegel (2011)
Assoziationen zwischen bildgebenden, kognitiven und motorischen Testverfahren zur Früherkennung des
Ärztlicher Direktor (2012)
10.1093/brain/awh391
Cholinergic systems in progressive supranuclear palsy.
N. Warren (2005)
Persian version of frontal assessment battery: Correlations with formal measures of executive functioning and providing normative data for Persian population
S. Asaadi (2016)
10.2147/nedt.2006.2.3.375
Problem solving therapy for the treatment of depression for a patient with Parkinson’s disease and mild cognitive impairment: a case study
R Scott Mackin (2006)
10.3390/jpm10020031
Application of Machine Learning Technique to Distinguish Parkinson’s Disease Dementia and Alzheimer’s Dementia: Predictive Power of Parkinson’s Disease-Related Non-Motor Symptoms and Neuropsychological Profile
Haewon Byeon (2020)
KÄELISTE OSKUSTE HINDAMINE ALZHEIMERI TÕVEGA JA PARKINSONI TÕVEST TINGITUD DEMENTSUSEGA PATSIENTIDEL Magistritöö
E. Tamme (2013)
10.1016/j.neuropsychologia.2014.07.016
Novelty processing and memory formation in Parkinson׳s disease
Judith Schomaker (2014)
10.32648/2639-3298/2/1/002
Donepezil and α-synuclein Constipation: A 36 Month Follow-Up
Charles M. Lepkowsky (2019)
Adherence therapy for people with Parkinson's disease
David James Daley (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar